Markus Queisser
@mqueisser.bsky.social
Reposted by Markus Queisser
If we were good at “validating” targets, the clinical trial failure rate likely wouldn’t be what it is. It’s an argument for large investment in basic disease biology and better model systems. No tech that churns out more compounds against the wrong target is gonna fix that. 15/
January 16, 2024 at 6:38 PM
If we were good at “validating” targets, the clinical trial failure rate likely wouldn’t be what it is. It’s an argument for large investment in basic disease biology and better model systems. No tech that churns out more compounds against the wrong target is gonna fix that. 15/
More to come soon, stay tuned….
December 6, 2023 at 10:00 AM
More to come soon, stay tuned….
Reposted by Markus Queisser
I liked that one!
A Rather Unwelcoming Degrader Enzyme
www.science.org
December 5, 2023 at 2:43 PM
I liked that one!